Emergent BioSolutions' COVID-19 Plasma Candidate To Be Tested As Outpatient Treatment

  • Emergent BioSolutions Inc EBS has announced the initiation of a Phase 3 trial that will evaluate its investigational SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG) plasma-derived therapy.
  • Related: Emergent BioSolutions' Plasma-Based Therapy Candidate Flunks COVID-19 Study.
  • The trial will assess the therapy as a potential outpatient treatment for patients at high risk of progression to severe disease, including adults 55 and older and those who are immunocompromised.
  • The NIAID-sponsored INSIGHT-012 study will evaluate the safety and efficacy of hyperimmune globulin products derived from plasma of individuals who have recovered from COVID-19 and have developed neutralizing antibodies. 
  • The randomized controlled clinical trial assigns participants to receive infusions of either a placebo or one of two hyperimmune globulin products, including Emergent's COVID-HIG, in addition to standard of care in all groups.
  • The trial plans to enroll approximately 800 patients.
  • Price Action: EBS shares closed 1.43% lower at $62.76 on Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechGovernmentNewsHealth CareGeneralBriefsCOVID-19 CoronavirusNational Institutes of HealthPhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!